AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Shareplus 302 object moved4/6/2023 ![]() ![]() AbbVie will continue to be led by Richard A. and have its principal executive offices in North Chicago, Ill. Upon completion of the transaction, AbbVie will continue to be incorporated in Delaware as AbbVie Inc. ![]() The combined companies generated $19 billion in operating cash flow in 2018. Significant cash flow generation: The success and scale of the combined commercial business ensures funding capacity and flexibility for simultaneous robust pipeline investment, debt reduction and capital return to shareholders.1 ROIC is expected to exceed AbbVie's cost of capital within the first full year. Financially attractive with immediate EPS accretion: This transaction is expected to be 10% accretive to adjusted earnings per share over the first full year following the close of the transaction, with peak accretion of greater than 20%.Immediate scale and enhanced profitability for AbbVie's growth platform: AbbVie's enhanced growth platform, comprised of growing and durable franchises across highly-attractive therapeutic areas, is expected to grow at a high-single digit annual growth rate well into the next decade, from more than $30 billion in 2020.Allergan's product portfolio will be enhanced by AbbVie's commercial strength, expertise and international infrastructure. New growth platforms and leadership positions to diversify and expand revenue base: The combined company will consist of several attractive franchises with leadership positions across immunology, hematologic oncology, medical aesthetics, neuroscience, women's health, eye care and virology."Our fast-growing therapeutic areas, including our world class medical aesthetics, eye care, CNS and gastrointestinal businesses, will enhance AbbVie's strong growth platform and create substantial value for shareholders of both companies." With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, an industry-leading R&D pipeline and robust cash flows, our combined company will have the opportunity to make even bigger contributions to global health than either can alone," said Brent Saunders, chairman and chief executive officer, Allergan. "This acquisition creates compelling value for Allergan's stakeholders, including our customers, patients and shareholders. With our enhanced growth platform to fuel industry-leading growth, this strategy allows us to diversify AbbVie's business while sustaining our focus on innovative science and the advancement of our industry-leading pipeline well into the future." "The combination of AbbVie and Allergan increases our ability to continue to deliver on our mission to patients and shareholders. Gonzalez, chairman and chief executive officer, AbbVie. "This is a transformational transaction for both companies and achieves unique and complementary strategic objectives," said Richard A. Transaction equity value of approximately $63 billion Allergan Shareholders will receive 0.8660 AbbVie Shares and $120.30 in cash for each Allergan Share, for a total consideration of $188.24 per Allergan Share Creates substantial value for shareholders of both companies and is expected to close in early 2020 Transaction delivers significant and immediate accretion and provides an attractive return on invested capital Combined company will produce robust cash flow to support continued dividend growth, further investment in the pipeline and reduction of debt levels ![]() Increases global commercial scale to further maximize the value of Allergan's attractive portfolio of fast-growing products Enhances long-term R&D funding capacity, allowing for continued investment and sustained focus on innovative science and advancement of an industry-leading pipeline Provides immediate scale and profitability to AbbVie's growth platform, excluding Humira, significantly expanding and diversifying its revenue base with new therapeutic areas, including Allergan's leading medical aesthetics business THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.5 OF THE IRISH TAKEOVER RULES NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION ![]()
0 Comments
Read More
Leave a Reply. |